HE-3235 is primarily investigated for its potential therapeutic applications in the field of oncology. It has shown promise as an anti-cancer agent, particularly in the treatment of hormone-sensitive cancers such as prostate cancer. The compound is believed to work by modulating hormone pathways, thereby inhibiting the growth and proliferation of cancer cells. Additionally, HE-3235 has been studied for its potential to enhance the efficacy of existing cancer therapies, making it a candidate for combination treatments. Research is ongoing to explore its full range of applications and to better understand its mechanisms of action in various cancer types.